WallStSmart

Alcon AG (ALC)vsEmbecta Corp (EMBC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 966% more annual revenue ($10.86B vs $1.02B). EMBC leads profitability with a 8.6% profit margin vs 5.9%. EMBC trades at a lower P/E of 3.4x. ALC earns a higher WallStSmart Score of 51/100 (C-).

ALC

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

EMBC

Hold

43

out of 100

Grade: D

Growth: 2.0Profit: 6.5Value: 5.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-22.2%)

Margin of Safety

-22.2%

Fair Value

$64.96

Current Price

$65.04

$0.08 premium

UndervaluedFair: $64.96Overvalued
EMBCSignificantly Overvalued (-41.7%)

Margin of Safety

-41.7%

Fair Value

$7.10

Current Price

$5.29

$1.81 premium

UndervaluedFair: $7.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

EMBC3 strengths · Avg: 9.3/10
P/E RatioValuation
3.4x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-2.4510/10

Conservative balance sheet, low leverage

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

Areas to Watch

ALC4 concerns · Avg: 2.8/10
Return on EquityProfitability
3.0%3/10

ROE of 3.0% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
50.5x2/10

Premium valuation, high expectations priced in

EMBC4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.564/10

Distress zone — elevated risk

Market CapQuality
$279.90M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-8.1%2/10

Revenue declined 8.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.18 suggests the stock is reasonably priced for its growth.

Bull Case : EMBC

The strongest argument for EMBC centers on P/E Ratio, Debt/Equity, Operating Margin.

Bear Case : ALC

The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 50.5x leaves little room for execution misses.

Bear Case : EMBC

The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.

Key Dynamics to Monitor

EMBC carries more volatility with a beta of 0.85 — expect wider price swings.

ALC is growing revenue faster at 8.7% — sustainability is the question.

ALC generates stronger free cash flow (414M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALC scores higher overall (51/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Embecta Corp

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.

Visit Website →

Want to dig deeper into these stocks?